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Introduction. This study estimates health-related quality
of life (HRQoL) or utility decrements associated with type
1 diabetes mellitus (T1DM) using data from a UK
research program on the Dose Adjustment For Normal
Eating (DAFNE) education program. Methods. A wide
range of data was collected from 2341 individuals who
undertook a DAFNE course in 2009–2012, at baseline and
for 2 subsequent years. We use fixed- and random-effects
linear models to generate utility estimates for T1DM
using different instruments: EQ-5D, SF-6D, and EQ-VAS.
We show models with and without controls for HbA1c
and depression, which may be endogenous (if, for exam-
ple, there is reverse causality in operation). Results. We
find strong evidence of an unobserved individual effect,
suggesting the superiority of the fixed-effects model.
Depression shows the greatest decrement across all the
models in the preferred fixed-effects model. The fixed-
effects EQ-5D model also finds a significant decrement
from retinopathy, body mass index, and HbA1c (%).
Estimating a decrement using the fixed-effects model is
not possible for some conditions where there are few new
cases. In the random-effects model, diabetic foot disease
shows substantial utility decrements, yet these are not
significant in the fixed-effects models. Conclusion. Utility
decrements have been calculated for a wide variety of
health states in T1DM that can be used in economic anal-
yses. However, despite the large data set, the low inci-
dence of several complications leads to uncertainty in
calculating the utility weights. Depression and diabetic
foot disease result in a substantial loss in HRQoL for
patients with T1DM. HbA1c (%) appears to have an inde-
pendent negative impact on HRQoL, although concerns
remain regarding the potential endogeneity of this vari-
able. Key words: type 1 diabetes; T1DM; EQ-5D; SF-6D;
EQ-VAS; health-related quality of life; depression;
HbA1c; utility. (Med Decis Making XXXX;XX:xx–xx)
For affected individuals, type 1 diabetes mellitus(T1DM) has a substantial impact on health-
related quality of life (HRQoL). The impact arises
through 1) long-term complications, both microvas-
cular (neuropathy [nerve damage], nephropathy
[kidney disease], and vision disorders [retinopathy,
glaucoma, cataracts]) and macrovascular (heart dis-
ease, stroke, peripheral vascular disease [which can
lead to ulcers and amputation]); 2) acute metabolic
complications such as episodes of hypoglycemia
and diabetic ketoacidosis (DKA) events; 3) fear and
anxiety around hypoglycemic and DKA episodes
and future health prospects; and 4) restrictions on
lifestyle and activities due to treatment regimen and
risk of diabetes-related complications and adverse
events.
Decision makers who use quality-adjusted life
years (QALYs) as a metric for the value of an inter-
vention require evidence on preference-based
health-related quality of life (or utilities [the term
utility in this context is used in a very general sense
as a reflection of value or how ‘‘good’’ a state would
be to live in]) of health states that are used within
economic decision models. A number of studies
have explored utility values for patients with
T1DM. Hahl and others1 considered the impact on
the 15D utility instrument using Finnish data on a
cross-sectional sample of n = 539. Ahola and
others2 also used the 15D but in a larger sample
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(n = 1023). Coffey and others3 and Tabaei and
others4 both analyzed a data set from Michigan to
explore the impact of health states on the Quality of
Well-being (QWA) utility instrument. Lee and
others5 elicited values from a time-tradeoff (TTO)
exercise for hypothetical diabetes-related states for
a sample of US adults with T1DM (n = 213). The
impact on the EQ-5D, which has particular rele-
vance in the UK context, has been considered only
in fairly small samples by Hart and others6 using a
patient sample from the Netherlands (n = 234) and
by Solli and others7 using a patient sample from
Norway (n = 165).
Many T1DM economic models have, to date,
used utilities estimated from patients with type 2
diabetes mellitus (T2DM). This is because utility
decrements for patients with T2DM have been esti-
mated based on large data sets. Clarke and others8
and Alva and others9 derived estimates from the
United Kingdom Prospective Diabetes Study
(UKPDS) cohort, and Bagust and Beale10 derived
estimates from the European CODE-2 data. It is plau-
sible, however, that utility values for health states of
T1DM might differ from those for T2DM because the
conditions differ in terms of etiology, epidemiology,
management, and risk of complications.11,12 Patients
with T1DM are typically younger and hence more
likely to be of working age, are likely to have had dia-
betes for longer, are less likely to be obese, and are
less likely to be socioeconomically deprived.13 Age,
for example, has been found to behave differently as
a predictor of self-reported health for people with
T2DM compared with T1DM.14
This study estimates utility decrements associ-
ated with diabetes-related health states for patients
with T1DM for use in economic models using data
obtained from a large UK research program focused
on the Dose Adjustment For Normal Eating
(DAFNE) education program. The DAFNE course is
a 5-day structured education program that aims to
give adults with T1DM the skills and confidence to
estimate the carbohydrate content of food and
adjust their insulin doses accordingly to maintain
acceptable glycemic control.15 Within the research
program, observational data were collected on a
wide range of clinical and HRQoL outcomes and
held in the DAFNE research database.16 The value
of the database in terms of research on utilities
arises, first, because it has a large sample size of
patients with T1DM (n = 2470 at baseline); second,
because there are 3 different utility measures avail-
able (EQ-5D, SF-6D, and EQ-VAS), which enables
us to explore differences and similarities between
these measures as they relate to diabetes-related
health states; and third, because there is a panel of
3 time periods, which allows us to take account of
unobserved individual effects within the analysis,
thereby removing a key potential for bias that arises
within cross-sectional data. These estimates are also
compared with those that have been estimated in
other studies for T1DM and T2DM.
METHOD
Description of Outcome Measures
The EQ-5D17 and SF-6D18 are generic HRQoL
questionnaires for which preference-based scores
(utility weights) have been developed for use in the
calculation of QALYs.
The EQ-5D-3L instrument comprises 5 questions
dealing with aspects of physical and mental health
(mobility, self-care, usual activities, pain/discom-
fort, anxiety/depression), for which the response is
1 of 3 possible degrees of impairment. Data from the
EQ-5D-3L were converted into utility values using
UK preference-based utility weights.19 EQ-5D is the
recommended utility measure for cost-effectiveness
analysis of health technologies in the United
Kingdom.20 The SF-12 questionnaire is a generic
12-item health status questionnaire21 developed
from the Short Form 36-item (SF-36) instrument.22
Data from the SF-12 were converted into the SF-6D
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utility values using UK weights.23 The EQ-VAS,
usually administered alongside the EQ-5D, is a
visual analog scale (VAS) used for recording an
individual’s rating of his or her current health. This
rating is anchored at 0 at the bottom (worst imagin-
able health state) and at 100 at the top (best imagin-
able health state).
These 3 utility instruments differ in a number of
key ways. SF-6D and EQ-5D use standard descrip-
tive systems to describe a particular health state.
These descriptive systems describe what the health
state is like in different ways. They use different
measurement periods, have different domains (e.g.,
the EQ-5D contains no domain for vitality), use a
different number of response choices for each
domain, and describe differing levels of severity.24
The EQ-5D can describe states that are of greater
severity than the SF-6D, but with only 3 response
options for each domain, it is less sensitive than the
SF-6D to mild changes in health states. The SF-6D
tends to have a larger percentage of respondents at
the floor (or worst) level for the physical dimen-
sions than the EQ-5D,25 making it less sensitive to
changes in health at the severe end.
Both of these measures allow us to link responses
to the descriptive questions to a utility score or
social tariff. These tariffs were derived from prefer-
ences from the general public who valued a sample
of health states described by the descriptive system
using methods that allow the scale to be anchored
at a point where a health state is equivalent to being
dead (TTO for the EQ-5D and standard gamble [SG]
for the SF-6D). These values were modeled to gener-
ate a social tariff for all health states on a scale on
which zero is equivalent to dead, 1 is equivalent to
full health, and states below zero are valued as
worse than dead. They reflect, therefore, the average
judgment of how good the general public thinks it
would be to live in each health state. The EQ-VAS
relies only on the individual’s judgment of his or her
own health state, and rather than focus on particular
domains of health-related quality of life, the individ-
ual’s judgment can incorporate anything the individ-
ual perceives as important. However, in generating
the value, the individual has not had to face a choice
or tradeoff; consequently, it is sometimes considered
a less accurate measure of preferences. Although the
EQ-VAS is rescaled to a 0–1 scale here, this is not
directly comparable to the 0 (dead) to 1 (full health)
scale used in the EQ-5D and SF-6D. The EQ-5D, SF-
6D, and VAS each offer a slightly different perspec-
tive on utility; it is therefore interesting to see how
they compare for T1DM states.
Data
All individuals within the DAFNE research data-
base undertook a DAFNE course, delivered to
groups of 6 to 8 patients over 5 consecutive days
during 2009 to 2012.26 Biomedical questionnaires
were completed by DAFNE educators (diabetes spe-
cialist nurse or dietitian who had access to medical
records), and DAFNE entrants completed a psycho-
social questionnaire prior to their education pro-
gram and again 1 and 2 years later. This survey
canvassed demographic, behavioral, and clinical
variables, as well as history of relevant clinical
events. In addition, various standard instruments
were used to collect HRQoL, including the EQ-5D,
EQ-VAS, and the SF-12. The variables used in sub-
sequent regression analyses are summarized in
Table 1. The utility weights are positively skewed.
The EQ-5D suffers from ceiling effects with about
50% of respondents in each time period reporting a
health state that is valued at 1 (see Table 1).
The format of the questionnaire at baseline meant
that patients report whether they are experiencing a
complication at that point in time, even though the
onset may be some years prior. The impact of com-
plications on HRQoL may not be constant over
time. For some degenerative conditions, longer
duration may result in greater negative impact; for
others, particularly where adaptation or recovery is
possible, the impact may reduce with time. The
follow-up data identify those who experience a new
complication during the follow-up period. For the
analysis, it is assumed that if a complication is
reported in previous years, that complication remains
present, unless they also report a greater severity. For
example, if an individual reports partial blindness at
baseline, this state is assumed to remain unless he or
she reports full blindness at follow-up. Depression is
assessed in each time period as defined by a case
according to the Hospital Anxiety and Depression
Score (HADS27).
Motivations
The initial model was determined by health
states required within a cost-effectiveness model.28
Steps to augment this model were influenced by an
understanding of the relationships between the
clinical outcomes and HRQoL, such as the extent to
which complications were asymptomatic, whether
their effect was direct, possible interactions
between outcomes, and the likely duration of any
impact.
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Table 1 Descriptive Summary of Variables: Sample from the DAFNE Research Database
Baseline 1 Year 2 Years
Variable Name
No.
(n = 2469
Unless
Indicated)
Mean
(SD) or
Frequency (%)
No.
(n = 1433
Unless
Indicated)
Mean
(SD) or
Frequency (%)
No.
(n = 602
Unless
Indicated)
Mean
(SD) or
Frequency (%)
Demographic/behavioral
Sex (male) 2467 51.4% 1431 49.9% 48.0%
Age, y 39.3 (13.8) 41.5 (13.6) 42.5 (14.0)
Duration, y 2449 16.3 (12.6) 1422 18.2 (13.1) 596 18.8 (13.2)
BMI, kg/m2 2320 26.4 (4.9) 1169 26.6 (4.8) 458 26.7 (5.3)
Born in United Kingdom 2465 76.2% 1431 73.7% 602 89.0%
Race (white) 2443 91.5% 1415 91.5% 598 90.0%
Smoking: current 2441 19.4% 1265 18.1% 478 13.8%
Former 24.9% 24.1% 23.6%
Never 55.7% 57.8% 62.6%
Pregnant 2393 1.3% 1433 1.9% 602 1.5%
Health outcomes
EQ-5D index 2341 0.839 (0.231) 1101 0.851 (0.236) 413 0.840 (0.234)
EQ-5D = 1 1164 (49.72%) 610 (55.40%) 210 (50.85%)
EQ-VAS 2292 69.4 (0.199) 1081 73.8 (0.181) 409 74.0 (0.186)
EQ-VAS = 100 53 (2.31%) 31 (2.87%) 14 (3.42%)
SF-6D index 2337 0.745 (0.137) 1081 0.765 (0.141) 403 0.773 (0.136)
SF-6D = 1 59 (2.52%) 41 (3.79%) 20 (4.96%)
Clinical/laboratory tests
HbA1c (%) 2351 8.8 (1.6) 1277 8.4 (1.4) 532 8.5 (1.5)
HbA1c IFCC mmol/mol
[HbA1c (%) – 2.15] 3 10.929
72.8 (17.8) 68.4 (15.8) 69.3 (16.4)
SBP, mm Hg 2278 128.5 (17.4) 1124 128.3 (16.5) 434 129.0 (17.6)
DBP, mm Hg 2278 75.8 (10.3) 1123 75.3 (9.8) 434 74.4 (10.2)
Depression
Taking antidepressant 2381 8.4% 1235 9.4% 481 10.2%
HADS score 11 2295 6.8% 1090 5.1% 413 5.1%
Complications (self-reported) Ever experienced to baseline New between baseline and follow-up New between year 1 and year 2
Hypertension 345 (14.0%) 11 (0.8%) 4 (0.7%)
Myocardial infarction 30 (1.2%) 1 (0.1%) 0
Coronary revascularization 23 (0.9%) 1 (0.1%) 0
Percutaneous intervention 9 (0.4%) 1 (0.1%) 0
Stroke 24 (1.0%) 3 (0.2%) 0
Painful neuropathy 118 (4.8%) 8 (0.6%) 3 (0.5%)
Painful neuropathy (only) 106 (4.29%) 6 (0.4%) 3 (0.5%)
Foot ulcer 42 (1.7%) 8 (0.6%) 4 (0.7%)
Foot ulcer, no amputation 30 (1.2%) 7 (0.5%) 4 (0.7%)
Amputation of toe(s) 14 (0.6%) 0 3 (0.3%)
Amputation above toes 8 (0.3%) 1 (0.1%) 0
Retinopathy 685 (27.7%) 28 (1.9%) 12 (1.9%)
Retinopathy (only) 554 (22.4%) 28 (1.9%) 11 (1.8%)
Proliferative 120 (4.86%) 3 (0.2%) 3 (0.5%)
Proliferative retinopathy (only) 113 (4.57%) 3 (0.2%) 3 (0.5%)
Partial blindness 20 (0.8%) 0 0
Blindness 3 (0.2%) 1 (0.1%) 0
Microalbuminuria 103 (4.2%) 5 (0.4%) 2 (0.3%)
(continued)
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We were particularly interested in whether
HbA1c had an independent impact on utility
values. Lowering HbA1c reduces the risk of micro-
vascular complications and may in the longer term
reduce the risk of cardiovascular events.29 Some
concern has been expressed that lower HbA1c
levels may also be related to weight gain and
increased risk of hypoglycemia.30,31 In addition,
better control may be achieved through greater com-
mitment to self-management by an increased com-
plexity of medical intervention and self-care, which
for some individuals may itself have a negative
impact on HRQoL. Analysis of DAFNE data has
found that the frequency of severe hypoglycemic
events reduced after DAFNE31 and led to an increase
in quality of life measured by the diabetes quality-of-
life instrument, the Audit of Diabetes-Dependent
Quality of Life (ADDQoL).32 Improved glycemic con-
trol has been found to be positively related to short-
term quality of life for patients with T2DM.33 Lower
HbA1c has also been associated with higher utility
values in people with T1DM in Finland.2
The relationship between utility and HbA1c
raises some interesting issues for the regression
analysis. First, we may not see an independent
effect of HbA1c if the benefit arises through reduced
risk of complications where these are fully con-
trolled for. Second, the benefit of a reduction in
HbA1c may be overestimated if weight and the fre-
quency of hypoglycemic events are controlled for.
Third, the relationship between HbA1c and quality
of life may be nonlinear.34
Events such as DKA and hypoglycemic episodes
are likely to have a direct impact on HRQoL while
they are being experienced and during the recovery
period.35 The utility measures administered at a
particular point in time may not identify this
trajectory of severe health shock followed by recov-
ery. There may also be an indirect impact relating
to the fear of future events (which is likely to be
related to DKA and hypoglycemic event fre-
quency36) and an impact from the restrictions that
the risk of these complications imposes upon
activities.
Table 1 (continued)
Baseline 1 Year 2 Years
Variable Name
No.
(n = 2469
Unless
Indicated)
Mean
(SD) or
Frequency (%)
No.
(n = 1433
Unless
Indicated)
Mean
(SD) or
Frequency (%)
No.
(n = 602
Unless
Indicated)
Mean
(SD) or
Frequency (%)
Microalbuminuria (only) 82 (3.3%) 5 (0.4%) 2 (0.3%)
Proteinuria 50 (2.0%) 6 (0.4%) 2 (0.3%)
Proteinuria (only) 48 (1.9%) 6 (0.4%) 2 (0.3%)
Dialysis (only) 3 (0.1%) 0 0
Renal transplantation 13 (0.5%) 0 0
Erectile dysfunction 132 (5.3%) 2(0.1%) 1(0.2%)
Diabetic events
DKAs last year 2383 1291 517
0 91.4% 97.4% 97.7%
1 6.5% 2.3% 1.9%
2 1.2% 0.2% -
3+ 0.9% 0.2% 0.4%
Severe hypos last year 2453 1273 503
0 78.4% 89.9% 90.5%
1 9.4% 5.0% 5.4%
2 4.4% 2.0% 1.8%
3 2.2% 1.0% 1.0%
4 1.4% 0.7% 0.8%
5+ 4.2% 1.4% 0.6%
The outcomes in this table do not allow for an assessment of the effectiveness of the Dose Adjustment For Normal Eating (DAFNE) intervention since
no allowance is made for dropout. This can be found in Hopkins and others.26 If individuals did not report a complication, it is assumed that they do
not have one (this arose for about a third of cases that had EQ-5D data). Where uncertainties existed or inconsistencies arose in the data, missing
fields were left blank. BMI, body mass index; DBP, diastolic blood pressure; DKA, diabetic ketoacidosis; HADS, Hospital Anxiety and Depression
Score; IFCC, International Federation of Clinical Chemistry; SBP, systolic blood pressure.
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Statistical Methods
There are 3 key challenges for the regression
analysis. The first is the bounded nature (utilities
cannot go above 1) and the positive skew of the util-
ity data, together with many values at full health.
The second is the risk of bias due to omitted, unob-
served variables, including the unobserved individ-
ual effect. We may identify a utility decrement from
a particular comorbidity, but patients with that
comorbidity may have had a lower utility value
prior to developing that comorbidity. The third,
related problem is that of attrition and missing data,
which may generate another source of bias.
The Tobit model37 is often recommended for bounded
scales, but biased and inconsistent parameter estima-
tors result in the presence of heteroskedastic errors.38
When the utility data were modeled using a Tobit
approach, Lagrange multiplier tests by auxiliary regres-
sions39 rejected the null hypothesis that the error var-
iances were normally distributed and homoskedastic.
Consequently, a linear approach was adopted, with
heteroskedasticity addressed through the use of a
robust Huber/White estimation of the variance-covar-
iance matrix.40
The use of longitudinal data opens the possibility
of addressing the problem of unobserved time-
invariant individual heterogeneity. With panel data,
we can consider changes in utility values over a
particular time period and diabetes-related events
occurring during that period. Relying only upon
change at the individual level would, in effect,
remove any unobserved individual effect.
Uit5a1bXit1uit:
uit5vi1eit:
vi;IDD (0,s
2
v):
eit;IDD (0,s2e ):
ð1Þ
For i = 1 . . . N and t = 1, 2, 3, where Ui are the mea-
sures of individual utility value at time t, X is a
vector of independent variables at time t, and b is a
vector of unknown parameters to be estimated. The
model can be estimated using a within (fixed-effect)
estimator that uses deviation from the individual
level mean of each variable, thereby removing the
unobserved time-invariant individual effect (vi)
from the model.
Uit Ui5ait  ai1b(Xit  Xi )1vi  vi1eit  ei: ð2Þ
However, in many cases, the complications we
are interested in have very few reported new cases
during follow-up (see Table 1). Using a restriction
of requiring at least 10 new cases during follow-up
results in dropping 12 of our variables of interest.
To explore a more complete model, we still rely on a
random-effects generalized least squares (GLS) model,
which gives weight to both the within-individual
variation and the between-individual variation. The
individual unobserved effect (vi) is treated as random
disturbance drawn from a specified distribution and
assumed to be uncorrelated with the covariates. This
uses the same model as (1) above but with the addi-
tional assumption that v and e are mutually indepen-
dent. It is important to note that bias might arise in
the random-effects model if the unobserved individ-
ual effect is correlated with the covariates; for exam-
ple, an unobserved individual trait such as
compliance or risk aversion might be correlated with
both outcomes and our covariates.
To explore the issue of attrition (both permanent
dropout and nonresponse for some waves), we use a
method developed by Heckman41 and employed in
a similar context by Alva and others.9 We run 2
selection models in which the dependent variable
is equal to 1 when we observe the individual
responding in the second wave and zero otherwise,
and similarly for the third wave, both based on cov-
ariates (including postcode area) from baseline data.
From these we estimate the inverse Mills ratio, a
transformation of the probability of participation for
each observation, which is then included in the
main model. If the coefficient on this variable is not
significantly different from zero, we can assume
that there is no correlation of the errors between our
main model and the selection model, and hence no
bias is created through attrition. We also consider
the variable addition test,42 which is simply a count
of the waves an individual has data for, where again
a coefficient that is not significantly different from
zero suggests no attrition bias. We further test
whether the coefficients derived from a balanced
sample of individuals with data in all 3 waves are
different from coefficients derived from an unba-
lanced sample in which individuals with incom-
plete data are included, based on a Hausman-type
test.43
The initial model included health states required
for the cost-effectiveness model28 and then added
covariates based on findings from the existing litera-
ture, clinical knowledge, and improving model
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performance as judged by the Akaike information
criterion (AIC). To ensure that the health states in
the regression model were mutually exclusive (as
required for populating economic models), individ-
uals were only assigned the most severe reported
state of progressive conditions. This applies to renal
failure states (where individuals progress from
microalbuminuria to proteinuria, then dialysis or
transplantation), vision states (where individuals
progress from retinopathy to proliferative retinopa-
thy to being registered partially sighted or blind),
and diabetic foot ulceration (where individuals
progress from painful neuropathy to foot ulcer to
amputation). Given that these foot states may arise
on one foot and then the other and that painful neu-
ropathy can exist on its own or in the presence of
foot ulceration,44 this progression is a simplification
designed to produce values for the mutually exclu-
sive states in economic models. Some categories
were combined (blind and partially sighted, ampu-
tation above the toe and amputation of toes, dialysis
and transplant) to ensure that all discrete predictor
variables had frequencies of at least 10.
Squared terms for each continuous predictor
variable were also considered. Where nonlinearities
in relationships were identified, further consider-
ation was given to whether the variables were best
transformed (e.g., taken logs), categorized, or taken
as deviation to the sample mean or relevant value.
Each of the outcome measures (EQ-5D, SF-6D,
and EQ-VAS) was modeled using a linear fixed-
effects and a GLS random-effects model. For each
outcome, we inspected graphs of predicted v. actual
values to consider how well the model performed
across the range of utility values. Data were ana-
lyzed using Stata version 12 (StataCorp LP, College
Station, Texas). An a value of 0.05 was used as a
guideline to determine statistical significance.
RESULTS
DAFNE baseline data were available on 2470
eligible subjects with 2341 (94.7%) having fully
completed the EQ-5D. Those with and without com-
plete EQ-5D at baseline were similar in terms of
background characteristics, treatment, and comor-
bidity profile. Twelve-month data were available on
1433 subjects (not all individuals had reached that
time point at the time of data extraction from the
DAFNE research database), of whom 1101 had EQ-
5D values. Two-year data were available on 602 sub-
jects, of whom 413 had EQ-5D values. For each time
period, the EQ-5D gave the highest average utility,
followed by the SF-6D, with the EQ-VAS giving the
lowest score (see Table 1), which is in line with our
expectations of these instruments.45
The selection models found that respondents
who did not report follow-up EQ-5D for the first
year (and similarly for the second year) were
younger, less likely to be born in the United
Kingdom, and had higher HbA1c at baseline (see
Suppl. Table S1). However, no evidence of attrition
bias was found based on the inclusion of the vari-
able for number of waves of data available or the
inverse Mills ratio in the full EQ-5D random-effects
model, both of which were insignificant (see Suppl.
Table S2). Nor were the coefficients from a balanced
panel for the EQ-5D different from those from the
unbalanced panel based on a Hausman test (see
Suppl. Table S3). Consequently, no correction was
made in the models for incomplete data.
The coefficients for the fixed-effects models are
shown in Table 2 (columns 1–3). In each case, a
modified Wald tests suggests heteroskedasticity,
and hence robust standard errors are used.
(Heteroskedasticity occurs when the variance of the
error term is not constant. In panel data, we may be
particularly concerned about groupwise heteroske-
dasticity where the variance of the error is specific
to an individual. The modified Wald test adopts a
null hypothesis that the variance is constant and
the test statistic [estimated using the stata command
xttest346] will be distributed as chi-squared under
this null hypothesis.) For all outcome measures, we
find evidence of an individual time-invariant error
term (based on modified Breusch-Pagan Lagrange
multiplier tests, which adopt a null hypothesis that
the variance of the unobserved, time-invariant indi-
vidual effect is zero) and evidence of correlation of
this individual error term with the other regressors,
suggesting the superiority of a fixed-effects model
(based on a Hausman test that compares the para-
meter estimates from the fixed- and random-effects
approaches. It adopts a null hypothesis that the
random effect is not correlated with the other regres-
sors, and hence the random-effect model would be
the preferred [most efficient] model. When the coeffi-
cients are found to be substantially different between
the 2 models [giving us a large and significant
Hausman statistic], we have reason to doubt this
assumption). However, we also show the random-
effects models to generate coefficients for conditions
where there is little change over time (columns 4–6).
The variance-covariance matrices for these models
are shown in Supplemental Table S4.
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Table 2 Impact of Diabetes Complications on Utilities from Dose Adjustment For Normal Eating Data on
People with Type 1 Diabetes Mellitus: Ordinary Least Squares Fixed-Effects Models and Generalized Least
Squares Random-Effects Models
Fixed-Effects Models, Coefficient (SE) Random-Effects Models, Coefficient (SE)
(1) EQ-5D (2) EQ-VAS (3) SF-6D (4) EQ-5D (5) EQ-VAS (6) SF-6D
Age (/10) –0.0214***
(0.003)
0.0092***
(0.003)
–0.0004
(0.002)
Female –0.0236**
(0.008)
–0.0270***
(0.007)
–0.0357***
(0.005)
Smoker –0.0027
(0.024)
–0.0432*
(0.025)
–0.0138
(0.013)
–0.0373**
(0.012)
–0.0466***
(0.010)
–0.0311***
(0.006)
BMI –0.0052**
(0.002)
–0.0040
(0.002)
–0.0008
(0.002)
–0.0028**
(0.001)
–0.0039***
(0.001)
–0.0013*
(0.001)
Born in the United Kingdom –0.0257**
(0.008)
0.0004
(0.008)
0.0027
(0.006)
MI –0.0242
(0.053)
–0.0876*
(0.038)
–0.0256
(0.029)
Stroke –0.0327
(0.048)
–0.0473
(0.042)
–0.0152
(0.025)
Microalbuminuria –0.0105
(0.028)
–0.0268
(0.021)
0.0118
(0.015)
Proteinuria –0.0277
(0.032)
–0.0334
(0.029)
–0.0143
(0.014)
Transplant or dialysis –0.0097
(0.050)
–0.0221
(0.030)
0.0029
(0.029)
Retinopathy –0.0544**
(0.023)
0.0075
(0.033)
–0.0111
(0.020)
–0.0265*
(0.011)
–0.0218*
(0.009)
–0.0116
(0.006)
Proliferative retinopathy –0.0288
(0.026)
–0.0113
(0.020)
–0.0242
(0.012)
Blind or partially sighted –0.0592
(0.062)
–0.0527
(0.029)
0.0220
(0.024)
Painful neuropathy –0.0497
(0.043)
–0.0997
(0.073)
–0.0578***
(0.020)
–0.2361***
(0.032)
–0.0835***
(0.022)
–0.0900***
(0.012)
Foot ulcer –0.1042
(0.119)
0.0316
(0.093)
–0.0536**
(0.023)
–0.1245*
(0.052)
–0.0995**
(0.032)
–0.0503**
(0.019)
Amputation (any) –0.1172*
(0.055)
–0.0321
(0.047)
–0.0592*
(0.027)
Erectile dysfunction –0.0310
(0.025)
–0.0122
(0.018)
–0.0179
(0.013)
Coronary revascularization –0.0787
(0.071)
–0.0021
(0.044)
–0.0090
(0.035)
Percutaneous revascularization 0.0250
(0.039)
0.0195
(0.035)
–0.0186
(0.036)
Hypertension –0.0265
(0.044)
–0.0404
(0.053)
–0.0163
(0.024)
–0.0144
(0.015)
–0.0128
(0.011)
–0.0131
(0.008)
Severe hypoglycemic
episodes in past year
–0.0020
(0.002)
–0.0023
(0.002)
–0.0030
(0.002)
–0.0022*
(0.001)
–0.0010
(0.001)
–0.0017**
(0.001)
DKA episodes in past year 0.0119
(0.011)
–0.0367**
(0.015)
–0.0021
(0.007)
–0.0091
(0.010)
–0.0265**
(0.010)
–0.0130***
(0.004)
HbA1c –0.0152***
(0.006)
–0.0099*
(0.006)
–0.0037
(0.004)
–0.0161***
(0.003)
–0.0164***
(0.002)
–0.0076***
(0.002)
Depression (HADS depression
score 11)
–0.0960***
(0.035)
–0.0831***
(0.026)
–0.0771***
(0.016)
–0.2520***
(0.026)
–0.1919***
(0.015)
–0.1589***
(0.008)
(continued)
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The impact of time-invariant covariates is shown
only in the random-effects model. Across all mea-
sures, women show significantly lower levels of
utility. Individuals who were not born in the
United Kingdom show lower utility for the EQ-5D
only. Time dummies rather than age are included in
fixed-effects model, and these show some improve-
ment in the SF-6D and EQ-VAS over time. This
effect is not picked up in the EQ-5D, and indeed, in
the random-effects model, age is negatively related
to the EQ-5D yet positively related to the EQ-VAS
score.
Being a current smoker is negatively and signifi-
cantly associated with all 3 utility measures in the
random-effects model and significantly so for the
fixed-effects model for the EQ-VAS, where it shares
a very similar effect size. BMI is negatively related
to all outcome measures in the random-effects
model and the fixed-effects EQ-5D (a 1-unit increase
in BMI results in a 0.0052 fall in the EQ-5D, but
only half that in the random-effects model).
The greatest utility decrement for both sets of
models arises due to experiencing depression. At
baseline, 8.4% of the sample take antidepressants
and 6.8% of the sample meet the criteria of ‘‘case-
ness’’ based on the HADS depression score (about a
third of whom are currently also taking antidepres-
sants). In the fixed-effects models, depression
reduces the EQ-5D by 0.096, the EQ-VAS by 0.0831,
and the SF-6D by 0.0771. These estimates are gener-
ated through individuals who change their depres-
sion state and are less than half those from the
random-effects model estimated through both
within and between individuals.
A substantial decrement is identified from pain-
ful neuropathy and foot ulcers. For neuropathy in
the random-effects models, the decrements are
0.2361 for the EQ-5D, 0.0835 for the EQ-VAS, and
0.0900 for the SF-6D. However, the high EQ-5D
decrement is not robust to the control for the indi-
vidual effect, and in the fixed-effects models, we find
a decrement of only 0.0497 (and nonsignificant) for
the EQ-5D, 0.0997 (and nonsignificant) for the EQ-
VAS, and 0.0578 for the SF-6D. Having experienced
amputation (only included in the random-effects
model) reduces the EQ-5D by 0.1172 and the SF-6D
by 0.0592. For the EQ-VAS, this is lower still (–0.0321
and nonsignificant). This may, again, be driven by the
small number of amputees (\1%).
The negative impact of having experienced a
stroke, coronary revascularization, microalbumi-
nuria, or proteinuria; having had dialysis or a trans-
plant; and the presence of hypertension was limited
in magnitude, which may be due to the sample
sizes for these comorbidities being relatively small.
For vision problems, retinopathy has a decrement
of around 0.0265 in the EQ-5D in the random-effects
model and 0.0544 in the fixed-effects model. The
EQ-VAS showed a decrement of 0.0218 for the
random-effects model, and the SF-6D was nonsigni-
ficant in both models. Proliferative retinopathy and
being blind or partially sighted, only included in
the random-effects models, had a roughly similar
magnitude of decrement but were not significant.
Again, this may arise due to having a small number
of individuals at baseline (1%) that experience
partial or full blindness, resulting in imprecise
estimates.
Table 2 (continued)
Fixed-Effects Models, Coefficient (SE) Random-Effects Models, Coefficient (SE)
(1) EQ-5D (2) EQ-VAS (3) SF-6D (4) EQ-5D (5) EQ-VAS (6) SF-6D
Wave 2 –0.0021
(0.007)
0.0160**
(0.007)
0.0159***
(0.005)
0.0038
(0.006)
0.0218***
(0.006)
0.0149***
(0.004)
Wave 3 –0.0019
(0.012)
0.0105
(0.011)
0.0166**
(0.008)
0.0052
(0.011)
0.0183*
(0.009)
0.0158*
(0.007)
Constant 1.1439***
(0.073)
0.9276***
(0.084)
0.8173***
(0.055)
1.2261***
(0.034)
0.9664***
(0.031)
0.8960***
(0.022)
Observations 2927 2895 2905 2917 2885 2895
Number of id 2044 2023 2029 2036 2015 2021
Rho 0.746 0.696 0.679 0.615 0.555 0.518
R2 overall 0.272 0.222 0.227
R2 within 0.042 0.052 0.057
Robust standard errors in parentheses. Rho is the proportion of the total variance that is due to the individual effect. BMI, body mass index; DKA, dia-
betic ketoacidosis; HADS, Hospital Anxiety and Depression Score; MI, myocardial infarction. *P\ 0.1. **P\ 0.05. ***P\ 0.01.
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The impact of severe hypoglycemic episodes is
negative but only significant in the random-effects
EQ-5D model (–0.0022) and random-effects SF-6D
model (–0.0017). DKA events are significantly nega-
tive for the EQ-VAS (lowering utility by 0.0367 in
the fixed-effects model and 0.0265 in the random-
effects model) and the SF-6D (lowering utility by
0.0130 per event in the random-effects model) but
are not significant for the EQ-5D.
HbA1c levels have a significant negative associa-
tion with all measures in the random-effects models
and the EQ-5D and EQ-VAS in the fixed-effects
models. A 1-unit increase (increase by 1%) in
HbA1c lowers the EQ-5D by 0.0161 in the random-
effects model and, very similarly, by 0.0152 in the
fixed-effects model. For the EQ-VAS, a 1% increase
lowers utility by 0.0164 in the random-effects
model and 0.0099 in the fixed-effects model. For
the SF-6D, a 1% increase lowers utility by 0.0076 in
the random-effects model and 0.0037 (and nonsigni-
ficant) in the fixed-effects model. These decrements
remained virtually unchanged when the controls
for weight and frequency of hypoglycemic episodes
were removed. No evidence was found of nonlinear-
ity (squared terms were not significant and reduced
model performance).
For each utility instrument, we also show 4
random-effects models with the gradual addition of
variables to the model (shown in Suppl. Tables S5–
S7). In most cases, the coefficients remain similar
following the introduction of additional covariates,
and the model fit improves based on the overall R2.
For the EQ-5D, we see a slight decline in coefficient
size for amputation as additional variables are
included, and for foot ulcers, the inclusion of
depression reduces the coefficient by at least a third
for the EQ-5D and SF-6D.
DISCUSSION
We find a considerable decrement arising from
the presence of depression, reducing the EQ-5D by
0.096 in the fixed-effects model. The inclusion
of the depression control is slightly problematic as
the HADS self-completed instrument may share
unobserved measurement biases with the SF-12 and
EQ-5D; for example, if the respondent was in a good
mood at the time of completion, this may result in a
positive bias on both the HADS and utility instru-
ments. Furthermore, we do not know whether the
depression in these cases has arisen due to the dia-
betes. The decrement on HRQoL of depression has
also been shown for patients with T2DM in cross-
sectional data, with Bagust and Beale10 estimating a
decrement of 0.202 for the EQ-5D and 9 (on 0–100
scale) for the EQ-VAS arising from a history of
depression. However, with T2DM, depression may
be a contributing factor to developing the disease,
making reverse causality more likely.47 The inclu-
sion of depression improves our models, and since
depression is a potential health state caused by
living with diabetes, it is important to estimate the
utility loss from this state.
We identify a large utility loss from diabetic foot
disease. The decrement estimated here from painful
neuropathy is larger than that found in the Bagust
and Beale10 T2DM data. The most severe neuropa-
thy in their cross-sectional ordinary least squares
(OLS) model has a decrement of 0.085, whereas
painful neuropathy in our random-effects model is
0.2361. This may be a result of how individuals
were classified in the 2 studies or due to a different
degree of severity or experience of neuropathy
between patients with T1DM and those with T2DM.
Solli and others7 also found that neuropathy results
in the greatest decrement in the EQ-5D for a sample
of patients with T1DM in Norway. This may indi-
cate potential problems using utility decrements for
painful neuropathy from patients with T2DM in
T1DM cost-effectiveness models. The DAFNE
cohort is considerably younger than the European
cohort used by Bagust and Beale (mean age of 39
years at baseline v. 67 years) and hence contains
many more individuals of working age; conse-
quently, painful neuropathy may have more impact
on their daily lives. The large decrement arising
from painful neuropathy is supported by the find-
ings by Currie and others,48 who found a close asso-
ciation between the EQ-5D and the Neuropathic
Total Symptom Score (NTSS-6-SA). However, the
decrement estimated here is not robust to the inclu-
sion of the individual fixed effect and hence may be
an overestimate. This suggests a need to explore the
impact on HRQoL of diabetic foot disease for
patients with T1DM in future work.
Almost all models identified an independent
impact on utility of HbA1c levels, which is slightly
greater for the EQ-5D and EQ-VAS than the SF-6D.
The impact on the EQ-5D in the fixed-effects model
is a 0.0152 decrease per unit increase in HbA1c (%).
This is greater than the decrement identified for
people with T1DM by Ahola and others2 using the
15D, who found a 1% increase to result in a 0.006
decline in the utility value using cross-sectional
data. Hart and others5 did not find HbA1c to be a
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significant predictor of the EQ-5D (or of subsequent
changes in the EQ-5D) in their data from the
Netherlands, although their sample size was small
(n = 234). However, there is reason to be concerned
about potential endogeneity, given that HbA1c does
not have an obvious direct impact on quality of life.
HbA1c may be correlated with time-variant unob-
servables; for example, individuals may experience
a new stressful event, which both results in a
decline in their ability to control blood glucose
levels and increases their probability of responding
at level 2 or 3 to the anxiety/depression item on the
EQ-5D. Furthermore, the direction of causality is a
little unclear. Poor overall health (as picked up by
the utility measures) may be contributing to the
higher HbA1c.
The lower utility value for women in T1DM and
T2DM is a common finding.2,3,9,10 Regarding BMI,
we expected this to show a slightly smaller impact
for patients with T1DM than T2DM, partly due to
existing estimates suggesting a smaller impact of
BMI on the 15D2 and QWB3 for T1DM and since
higher BMIs contribute directly to the development
and progression of T2DM itself. However, the esti-
mate for the decrement in the EQ-5D for BMI in the
fixed-effects model is 0.0052 per unit of BMI and
0.0028 in the random-effects model; these are very
similar to the 0.006 decrement in the EQ-5D esti-
mated in Bagust and Beale10 on cross-sectional
data. Decrements in the VAS scale are also broadly
similar.
Due to small sample sizes, it is difficult to see
robust significant decrements for some long-term
complications. Coefficients, such as those for stroke
and myocardial infarction (MI), while mostly non-
significant, still appear very small relative to other
estimates for T2DM such as those from Alva and
others.9
Comparisons to utility decrements estimated for
T2DM and T1DM within the existing literature are
problematic due to the many nonsignificant find-
ings for complications with the DAFNE data and
differences in models and covariates used across
the literature. Critically, existing models that are
based on cross-sectional data do not control for
unobserved individual heterogeneity and hence are
likely to systematically overpredict the impact of
complications.9 Our analysis finds clear support for
the need to address the unobserved individual
effect.
Comparing our estimates to those drawn from
hypothetical TTO questions with adults with dia-
betes, we see much lower utility values in the TTO
estimates. For example, Lee and others5 found esti-
mates of 0.52 for blindness, 0.47 for end-stage renal
disease, 0.74 for angina, 0.34 for severe stroke, and
0.73 for amputation. It is difficult to make these
comparisons for a number of reasons. First, we have
limited numbers of patients with certain conditions,
making precise estimates difficult. Second, our esti-
mates control for decrements arising from other
aspects (such as weight, age, other conditions, fre-
quency of complications such as DKA). Third, our
estimates also cover a range of severity and time
since the condition, and we would expect certain
conditions (such as stroke) to have a different
impact across the severity level of strokes and time
since the stroke occurred.
Estimates derived from hypothetical TTO esti-
mates49 identified a reduction in utility of 0.0033
for each nonsevere hypoglycemic event, broadly
similar to the 0.0022 decrement identified in the
EQ-5D random-effects model for severe hypoglyce-
mic events (which is supported by a similar [0.0020]
but nonsignificant fixed-effects coefficient). Some of
the impact of hypoglycemic events may be mediated
via fear,50 but we do not find the coefficient to
decrease following the inclusion of depression.
Aggregating categories such as partially sighted
and blindness is problematic, since we would
anticipate a different impact for these 2 categories.
Indeed, the division should arguably be much finer
after taking into consideration the deterioration in
each eye. The sensitivity of these measures to vision
deterioration has been questioned51; however, we
do detect a significant negative impact of having
retinopathy on both the EQ-5D (around –0.0544 in
the fixed-effects model) and the EQ-VAS (–0.0218
in the random-effects model). This is broadly in line
with findings from Hart and others,6 who found
new cases of retinopathy to result in a decrease in
the EQ-5D of 0.048. Brown and others52 also found
a decrement for retinopathy using direct patient
valuations (TTO and SG).
The comparison between the EQ-VAS, SF-6D,
and EQ-5D does not show any clear patterns. We
anticipated that the SF-6D would be more sensitive
to mild changes in health, whereas the EQ-5D might
show a greater decrement for more severe health
states.53 Indeed, the EQ-5D can give a much lower
possible value to a health state than is possible with
the SF-6D: the minimum value possible for the EQ-
5D is –0.594, with a minimum value in this data set
of –0.239, but for the SF-6D, the minimum possible
value is only 0.29, with a minimum value in this
data set of 0.345.54 In almost all cases where the
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SF-6D is significant, it shows a smaller decrement
size, with a smaller standard error, compared with
the EQ-5D. The number of DKA episodes per year is
the only covariate that shows significance in the
SF-6D (and EQ-VAS) but not the EQ-5D, which
might suggest that the SF-6D is better at picking up
episodic events. Experiencing an MI is the only cov-
ariate that shows a greater decrement on the EQ-
VAS than the other instruments, which are non-
significant. The instruments tell a similar story
about which health consequences will be identified
in utility instruments, but they are not identical
(the conflicting relationship with age is a case in
point). The extent to which these differences matter
will depend on the importance of small changes in
utility values within the cost-effectiveness model.
Will our findings generalize to other populations
of people with T1DM? These findings are based on
a survey, which may introduce bias, but the spread
of information required for an analysis of this type
is only available in a research database rather than
in one used for routine clinical practice. There are
incomplete data on the sample over the 3 years,
with those with poor health most likely to drop out
of the sample. However, the sample selection tests
undertaken to explore the potential impact of attri-
tion find that the impact on our estimates is likely
to be minimal.
Although the random-effects model provides
more complete estimates for the range of diabetes-
related health states, it still rests on the assumption
that the unobserved individual effect is not corre-
lated with the any of the covariates. While we can
be more confident in the estimates derived from the
fixed-effects model, the lack of change at the indi-
vidual level means we are unable to generate esti-
mates for many important health states.
Data rely on patient completed preference-based
measures (EQ-5D and SF-6D) along with patient-
completed VAS. Other options include other instru-
ments (such as HUI3, 15D, and QWB) or direct
valuation (using methods such as TTO and SG)
with patients, with valuation of vignettes either by
patients or the general public. A key advantage of
relying on preference-based measures is that we are
not relying on potentially limited understanding of
what it might be like to live in a hypothetical health
state. Furthermore, in diabetes patients, we may
expect patients to have a number of different comor-
bidities and complications. Relying on direct values
from patients based on utility instruments reflects
that more complex picture.
CONCLUSIONS
The analysis of the DAFNE research database
provides utility estimates based on panel data on
diabetes-related health states to populate economic
models exploring the cost-effectiveness of interven-
tions for patients with T1DM. The models improve
upon existing available estimates due to the large
sample size available across 3 time periods, which
enables analysis using the preferred fixed-effects
approach. However, even with the large data set avail-
able, it is still difficult to identify robust estimates for
many complications due to the small number of
patients who experience some complications.
Comparing the decrements in EQ-5D for comor-
bidities, complications, and diabetes-related events
in people with T1DM and T2DM suggests broadly
similar decrements. For complications with a low
frequency (such as stroke, MI, dialysis, transplant,
and blindness) where T1DM utility values from
preference-based measures are not available to use
in economics models, using either direct valuation
of states (preferably with patients with diabetes
[e.g., Lee and others5]) or T2DM utility values is rea-
sonable. However, future work should look to
extended T1DM panel data to allow improved
estimates.
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